Clinical Study of Pregabalin Combined with Longdan Quanxiong Decoction in Treating Postherpetic Neuralgia
ZHOU Xiaoyu
CHEN Shiyuan
ZHOU Shuxiang
JING Hua
Abstract：Objective To observe the clinical efficacy and safety of pregabalin combined with Longdan Quanxiong Decoction in treating postherpetic neuralgia(PHN).Methods From January 2023 to August 2024,a total of 42 patients with PHN were recruited from the Department of Traditional Chinese Medicine of PLA Naval Medical Center(15 cases)and the Department of Dermatology of Yancheng Yandu District Center for Disease Control and Prevention(27 cases).They were randomized 1:1 to receive pregabalin capsules(control group)and pregabalin combined with Longdan Quanxiong Decoction(treatment group)for 20 days.The visual analogue scale(VAS)score,serum interleukin-17(IL-17),prostaglandin E2(PGE2),C-reactive protein(CRP)levels,clinical efficacy,adverse reactions and onset time were compared between the two groups before and after treatment.Results After treatment,VAS scores,IL-17,CRP,and PGE2 levels were significantly decreased in both groups compared to pre-treatment(P<0.05),with a significantly reduction in the treatment group(P<0.05).The therapeutic efficacy of the treatment group was significantly higher than that of the control group(P<0.05),and the average onset time was significantly shorter than that of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of pregabalin and Longdan Quanxiong Decoction is safe and effective in the treatment of PHN.
Keywords：postherpetic neuralgiapregabalinLongdan Quanxiong Decoctioninterleukin 17prostaglandin E2
Publication Date：2025-12-10
Online Publishing Date：2026-01-04(First online date of this platform, not the publication date of the document)
Pages：5( 469-473 )